Patient-centred, self-funding dose optimisation trials as a route to reduce toxicity, lower cost and improve access to cancer therapy.

[1]  S. Aebi,et al.  Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial , 2023, Leukemia.

[2]  A. Bhattacharjee,et al.  Retrospective analysis: checkpoint inhibitor accessibility for thoracic and head and neck cancers and factors influencing it in a tertiary centre in India , 2022, Ecancermedicalscience.

[3]  I. Tannock,et al.  Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global access , 2022, Nature Medicine.

[4]  W. Organization.  World Health Organization model list of essential medicines for children – 8th list, 2021 , 2022, Yearbook of Paediatric Endocrinology.

[5]  I. Tannock,et al.  The dosing of ibrutinib and related Bruton’s tyrosine kinase inhibitors: eliminating the use of brute force , 2022, Blood advances.

[6]  G. Bouche,et al.  Ensuring completeness and timeliness of cancer treatment guidelines , 2022, Nature Reviews Clinical Oncology.

[7]  D. Goldstein,et al.  Enabling the Sharing of Single-Dose Vials Through Risk Mitigation to Decrease Financial Toxicity. , 2022, JAMA oncology.

[8]  E. Eisenhauer,et al.  The Time Toxicity of Cancer Treatment. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  I. Tannock,et al.  Improving Access to Immunotherapy in Low and Middle-Income Countries. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  M. Ratain,et al.  Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation , 2021, Journal of clinical pharmacology.

[11]  R. Pazdur,et al.  The Drug-Dosing Conundrum in Oncology - When Less Is More. , 2021, The New England journal of medicine.

[12]  I. Tannock,et al.  Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message? , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Jager,et al.  A revolving research fund to study efficient use of expensive drugs: big wheels keep on turning. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  A. Wolff,et al.  Patient perspectives on chemotherapy de‐escalation in breast cancer , 2021, Cancer medicine.

[15]  G. Rosner,et al.  Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Ratain,et al.  Ibrutinib's Cardiotoxicity-An Opportunity for Postmarketing Regulation. , 2020, JAMA oncology.

[17]  E. Winer,et al.  Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  G. Pond,et al.  A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer , 2020, European Journal of Cancer.

[19]  S. Kannan,et al.  Evaluation of 1-Year vs Shorter Durations of Adjuvant Trastuzumab Among Patients With Early Breast Cancer , 2020, JAMA network open.

[20]  C. Caldas,et al.  Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK , 2020, Clinics in oncology.

[21]  M. Ratain,et al.  Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19. , 2020, JAMA oncology.

[22]  M. Ratain,et al.  Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value. , 2020, Clinical pharmacology and therapeutics.

[23]  I. Tannock,et al.  Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets , 2020, JCO global oncology.

[24]  Andrew Copas,et al.  Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation , 2019, Trials.

[25]  M. Gail,et al.  The Need for Combined Assessment of Multiple Outcomes in Noninferiority Trials in Oncology. , 2019, JAMA oncology.

[26]  M. Ratain,et al.  Alternative dosing regimens for atezolizumab: right dose, wrong frequency , 2019, Cancer Chemotherapy and Pharmacology.

[27]  M. Ratain,et al.  Interventional Pharmacoeconomics-A New Discipline for a Cost-Constrained Environment. , 2019, JAMA oncology.

[28]  P. Postmus,et al.  Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  C. Tournigand,et al.  6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial , 2019, The Lancet.

[30]  C. Caldas,et al.  6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial , 2019, The Lancet.

[31]  Xuelin Huang,et al.  A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. , 2018, Blood.

[32]  M. Ratain,et al.  Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Vinay Prasad,et al.  Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval , 2017, JAMA internal medicine.

[34]  G. Hortobagyi,et al.  Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial , 2017, JAMA oncology.

[35]  John D. Roberts,et al.  Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial , 2017, JAMA.

[36]  C. Kollmannsberger,et al.  Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer , 2015, Journal of clinical pharmacology.

[37]  Lon Smith,et al.  Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.

[38]  R. Motzer,et al.  Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  R. Herrmann,et al.  Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  T. Tammela,et al.  Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. , 2014, The Lancet. Oncology.

[41]  D. Amadori,et al.  Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. , 2013, The Lancet. Oncology.

[42]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[43]  R. Badwe,et al.  Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. , 2011, Indian journal of cancer.

[44]  Israel Lowy,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  J. Humm,et al.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.

[46]  Mitch Dowsett,et al.  Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  S. Garattini,et al.  Non-inferiority trials are unethical because they disregard patients' interests , 2007, The Lancet.